GlassScriptPhysician profile
James L Bumgartner
NPI 1477522845
$9,705.58
in general payments reported to CMS, 2019-2025
59 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $1,108 · 2021: $1,814 · 2022: $1,701 · 2023: $1,544 · 2024: $1,405 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,966.81 | 2019-2025 | |
| Abbvie INC. | $1,319.28 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Ucb, INC. | $582.63 | 2020-2025 | Briviact, Rystiggo |
| Celgene Corporation | $555.64 | 2021-2025 | Zeposia |
| Pfizer INC. | $483.01 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $383.66 | 2019-2022 | |
| Emd Serono, INC. | $352.76 | 2019-2023 | Mavenclad |
| Acadia Pharmaceuticals INC | $333.06 | 2019-2025 | Nuplazid |
| Mdd US Operations, LLC | $324.30 | 2022-2024 | Gocovri, Apokyn, Myobloc |
| Biogen, INC. | $310.71 | 2020-2024 | Skyclarys |
| Sk Life Science, INC. | $234.79 | 2022-2025 | |
| Amgen INC. | $206.04 | 2021-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $138.65 | 2020-2025 | Austedo Xr, Ajovy |
| E.R. Squibb & Sons, L.L.C. | $135.43 | 2020-2021 | |
| Genzyme Corporation | $132.30 | 2020-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.